Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer

Pembrolizumab, an immune checkpoint inhibitor (ICI) approved for advanced non-small cell lung cancer (NSCLC) treatment, has shown superior survival benefits. However, pembrolizumab may lead to severe immune-related adverse events (irAEs), such as checkpoint inhibitor-related pneumonitis (CIP). The r...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiao-Hong, Deng, Hai-Yi, Lin, Xin-Qing, Wu, Jian-Hui, Liu, Ming, Xie, Zhan-Hong, Qin, Yin-Yin, Zhou, Cheng-Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249753/
https://www.ncbi.nlm.nih.gov/pubmed/34221992
http://dx.doi.org/10.3389/fonc.2021.673877
_version_ 1783716963310108672
author Xie, Xiao-Hong
Deng, Hai-Yi
Lin, Xin-Qing
Wu, Jian-Hui
Liu, Ming
Xie, Zhan-Hong
Qin, Yin-Yin
Zhou, Cheng-Zhi
author_facet Xie, Xiao-Hong
Deng, Hai-Yi
Lin, Xin-Qing
Wu, Jian-Hui
Liu, Ming
Xie, Zhan-Hong
Qin, Yin-Yin
Zhou, Cheng-Zhi
author_sort Xie, Xiao-Hong
collection PubMed
description Pembrolizumab, an immune checkpoint inhibitor (ICI) approved for advanced non-small cell lung cancer (NSCLC) treatment, has shown superior survival benefits. However, pembrolizumab may lead to severe immune-related adverse events (irAEs), such as checkpoint inhibitor-related pneumonitis (CIP). The routine treatment of CIP was based on systemic corticosteroids, but the therapies are limited for patients who are unsuitable for steroid therapy. Here, we present the first successful treatment of nintedanib for pembrolizumab-related pneumonitis in a patient with advanced NSCLC.
format Online
Article
Text
id pubmed-8249753
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82497532021-07-03 Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer Xie, Xiao-Hong Deng, Hai-Yi Lin, Xin-Qing Wu, Jian-Hui Liu, Ming Xie, Zhan-Hong Qin, Yin-Yin Zhou, Cheng-Zhi Front Oncol Oncology Pembrolizumab, an immune checkpoint inhibitor (ICI) approved for advanced non-small cell lung cancer (NSCLC) treatment, has shown superior survival benefits. However, pembrolizumab may lead to severe immune-related adverse events (irAEs), such as checkpoint inhibitor-related pneumonitis (CIP). The routine treatment of CIP was based on systemic corticosteroids, but the therapies are limited for patients who are unsuitable for steroid therapy. Here, we present the first successful treatment of nintedanib for pembrolizumab-related pneumonitis in a patient with advanced NSCLC. Frontiers Media S.A. 2021-06-18 /pmc/articles/PMC8249753/ /pubmed/34221992 http://dx.doi.org/10.3389/fonc.2021.673877 Text en Copyright © 2021 Xie, Deng, Lin, Wu, Liu, Xie, Qin and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xie, Xiao-Hong
Deng, Hai-Yi
Lin, Xin-Qing
Wu, Jian-Hui
Liu, Ming
Xie, Zhan-Hong
Qin, Yin-Yin
Zhou, Cheng-Zhi
Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
title Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
title_full Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
title_fullStr Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
title_full_unstemmed Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
title_short Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer
title_sort case report: nintedanib for pembrolizumab-related pneumonitis in a patient with non-small cell lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249753/
https://www.ncbi.nlm.nih.gov/pubmed/34221992
http://dx.doi.org/10.3389/fonc.2021.673877
work_keys_str_mv AT xiexiaohong casereportnintedanibforpembrolizumabrelatedpneumonitisinapatientwithnonsmallcelllungcancer
AT denghaiyi casereportnintedanibforpembrolizumabrelatedpneumonitisinapatientwithnonsmallcelllungcancer
AT linxinqing casereportnintedanibforpembrolizumabrelatedpneumonitisinapatientwithnonsmallcelllungcancer
AT wujianhui casereportnintedanibforpembrolizumabrelatedpneumonitisinapatientwithnonsmallcelllungcancer
AT liuming casereportnintedanibforpembrolizumabrelatedpneumonitisinapatientwithnonsmallcelllungcancer
AT xiezhanhong casereportnintedanibforpembrolizumabrelatedpneumonitisinapatientwithnonsmallcelllungcancer
AT qinyinyin casereportnintedanibforpembrolizumabrelatedpneumonitisinapatientwithnonsmallcelllungcancer
AT zhouchengzhi casereportnintedanibforpembrolizumabrelatedpneumonitisinapatientwithnonsmallcelllungcancer

Ejemplares similares